Four types of needles available
Link Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D
Share your link with friends and earn a reward when they purchase
Safety and Tolerability Both compounds share a dominant, mostly mild-to-moderate gastrointestinal adverse-event profile nausea, vomiting, diarrhea, constipation, abdominal pain concentrated during dose escalation
What they found: In normal obese mice: AOD-9604 reduced body fat by 21 % vs placebo, hGH by 24 % The AOD-9604 effect was fully dependent on the 3-adrenergic receptor , in knock-out mice no effect The hGH effect was partly independent of 3-AR , in knock-out mice there was still ~10 % fat reduction AOD-9604 did not raise IGF-1 (control level), whereas hGH raised IGF-1 by 80 % No changes in growth, organ weights (except adipose tissue), fasting insulin Why it matters: The study provided the mechanistic basis for AOD-9604 and confirmed the key business hypothesis: it is possible to separate the lipolytic effect of GH from its growth effect
What concentration are you taking it in